Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-21 7:14 pm Unchanged |
2025-03-19 | 13G | Cue Biopharma, Inc. CUE |
Bleichroeder LP | 6,127,662 9.990% |
0 (Unchanged) |
Filing History |
| 2025-02-14 5:00 pm Sale |
2024-12-31 | 13G | Cue Biopharma, Inc. CUE |
Slate Path Capital LP | 918,836 1.400% |
-1,483,619 (-61.75%) |
Filing History |
| 2024-10-07 5:07 pm Purchase |
2024-09-30 | 13G | Cue Biopharma, Inc. CUE |
Bleichroeder LP | 6,127,662 9.990% |
3,372,634 (+122.42%) |
Filing History |
| 2024-03-11 6:40 pm Purchase |
2024-02-27 | 13G | Cue Biopharma, Inc. CUE |
Bleichroeder LP | 2,755,028 6.110% |
2,755,028 (New Position) |
Filing History |
| 2024-02-07 5:09 pm Sale |
2024-01-31 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
2,247,978 4.980% |
-90,787 (-3.88%) |
Filing History |
| 2024-01-31 2:08 pm Purchase |
2023-12-31 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
2,338,765 5.200% |
1,506,840 (+181.13%) |
Filing History |
| 2023-02-14 09:30 am Unchanged |
2022-12-31 | 13G | Cue Biopharma, Inc. CUE |
Slate Path Capital LP | 2,402,455 5.600% |
0 (Unchanged) |
Filing History |
| 2023-02-03 11:36 am Sale |
2022-12-31 | 13G | Cue Biopharma, Inc. CUE |
STATE STREET CORP STT |
141,153 0.330% |
-1,521,099 (-91.51%) |
Filing History |
| 2022-12-02 5:21 pm Sale |
2022-12-01 | 13G | Cue Biopharma, Inc. CUE |
Nantahala Capital Management, LLC | 93,297 0.300% |
-2,446,403 (-96.33%) |
Filing History |
| 2022-11-18 4:04 pm Purchase |
2022-11-16 | 13G | Cue Biopharma, Inc. CUE |
Slate Path Capital LP | 2,402,455 5.600% |
2,402,455 (New Position) |
Filing History |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
831,925 2.400% |
-1,458,344 (-63.68%) |
Filing History |
| 2022-02-14 4:23 pm Sale |
2021-12-31 | 13G | Cue Biopharma, Inc. CUE |
Corriente Advisors LLC | 0 0.000% |
-1,915,219 (Position Closed) |
Filing History |
| 2022-02-14 08:09 am Purchase |
2021-12-31 | 13G | Cue Biopharma, Inc. CUE |
Nantahala Capital Management, LLC | 2,539,700 8.000% |
32,928 (+1.31%) |
Filing History |
| 2022-02-10 1:52 pm Purchase |
2021-12-31 | 13G | Cue Biopharma, Inc. CUE |
STATE STREET CORP STT |
1,662,252 5.230% |
1,662,252 (New Position) |
Filing History |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
2,290,269 7.200% |
127,291 (+5.88%) |
Filing History |
| 2021-02-16 06:28 am Purchase |
2020-12-31 | 13G | Cue Biopharma, Inc. CUE |
Corriente Advisors LLC | 1,915,219 6.330% |
1,915,219 (New Position) |
Filing History |
| 2021-02-12 3:19 pm Purchase |
2020-12-31 | 13G | Cue Biopharma, Inc. CUE |
Nantahala Capital Management, LLC | 2,506,772 8.300% |
1,101,831 (+78.43%) |
Filing History |
| 2021-02-12 08:13 am Sale |
2020-12-31 | 13G | Cue Biopharma, Inc. CUE |
AVORO CAPITAL ADVISORS LLC | 452,500 1.500% |
-1,417,500 (-75.80%) |
Filing History |
| 2021-01-29 09:56 am Purchase |
2020-12-31 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
2,162,978 7.100% |
775,309 (+55.87%) |
Filing History |